$0.89
+0.05 (+5.89%)
Open$0.82
Previous Close$0.84
Day High$0.91
Day Low$0.82
52W High$25.80
52W Low$9.55
Volume—
Avg Volume168.5K
Market Cap133.32M
P/E Ratio47.65
EPS$0.39
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,179.0% upside
Current
$0.89
$0.89
Target
$20.19
$20.19
$14.44
$20.19 avg
$28.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.90M | 15.53M | 15.53M |
| Net Income | 2.54M | 3.35M | 2.88M |
| Profit Margin | 17.0% | 21.6% | 18.5% |
| EBITDA | 5.18M | 5.39M | 5.26M |
| Free Cash Flow | 2.62M | 3.23M | 2.70M |
| Rev Growth | -8.5% | -1.6% | +3.5% |
| Debt/Equity | 0.17 | 0.17 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |